Commerzbank Aktiengesellschaft FI raised its holdings in Iqvia Holdings Inc (NYSE:IQV) by 27.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,768 shares of the medical research company’s stock after purchasing an additional 1,906 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Iqvia were worth $1,310,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the business. CWM LLC lifted its stake in shares of Iqvia by 63.4% in the 2nd quarter. CWM LLC now owns 165 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 64 shares during the last quarter. Capital Investment Advisory Services LLC lifted its stake in shares of Iqvia by 46.0% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 69 shares during the last quarter. Massmutual Trust Co. FSB ADV bought a new position in shares of Iqvia in the 2nd quarter valued at $35,000. Massey Quick Simon & CO. LLC bought a new position in shares of Iqvia in the 3rd quarter valued at $43,000. Finally, North Star Investment Management Corp. bought a new position in shares of Iqvia in the 3rd quarter valued at $59,000. 90.65% of the stock is currently owned by hedge funds and other institutional investors.
NYSE:IQV traded up $0.63 during trading hours on Wednesday, hitting $143.57. 930,833 shares of the company were exchanged, compared to its average volume of 1,292,284. The stock has a market capitalization of $26.70 billion, a price-to-earnings ratio of 28.04, a price-to-earnings-growth ratio of 1.52 and a beta of 0.87. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85. Iqvia Holdings Inc has a one year low of $104.90 and a one year high of $164.13. The company has a fifty day simple moving average of $145.60 and a 200 day simple moving average of $148.35.
A number of research analysts have recently commented on the company. Wells Fargo & Co increased their price target on Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Credit Suisse Group increased their price target on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. increased their price target on Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $166.46.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: 52-Week High/Low
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.